Omnicell

Valuation Analysis

About the Company

Omnicell en bref

Omnicell (OMCL) is currently trading at 30,67 € with a market capitalization of 1,4 Md €. The trailing P/E ratio stands at 42.11x, with a forward P/E of 16.36x. The 52-week range spans from 25,20 € to 47,69 €; the current price is 35.7% below the yearly high. Year-over-year revenue growth stands at +7.5%. The net profit margin stands at 3.14%.

💰 Dividende

Omnicell currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Omnicell (OMCL) au consensus : Achat Fort. L'objectif de cours moyen est de 51,40 €, soit un potentiel de +67.62% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 43,35 € à 60,69 €.

Omnicell : la thèse d'investissement en détail

Omnicell (OMCL) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 333.3% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Strong Buy with an average price target implying roughly 67.62% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 3.14%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 15.4, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 16.36x is meaningfully below the trailing 42.11x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 67.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.58%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Omnicell?

Compare top-rated brokers — low fees, trusted providers, fully regulated.